01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Study design and participants
Outcomes and follow-up
Data collection
Statistical analysis
Results
Study participants
Characteristic
|
All patients
(
n = 182)
|
---|---|
Age (years)
|
65.1 ± 9.4
|
Male sex
|
135 (74.2)
|
Smoker
|
139 (76.4)
|
Hypertension
|
67 (36.8)
|
Antihypertensive medication
|
51 (28.0)
|
Calcium channel blockers
|
35 (19.2)
|
RAS inhibitors
|
31 (17.0)
|
Others
|
14 (7.7)
|
Diabetes
|
25 (13.7)
|
Cardiovascular disease
|
10 (5.5)
|
Cancer types
|
|
Esophagus
|
82 (45.1)
|
Head and neck
|
77 (42.3)
|
Stomach
|
23 (12.6)
|
Combined anticancer drugs
|
138 (75.8)
|
5-FU
|
108 (59.3)
|
TS-1
|
19 (10.4)
|
DOC
|
14 (7.7)
|
CPT-11
|
5 (2.7)
|
Capecitabine
|
5 (2.7)
|
Development of cisplatin nephrotoxicity
Risk factors for cisplatin nephrotoxicity
Characteristic
|
Nephrotoxicity (+)
|
Nephrotoxicity (−)
|
P value
|
---|---|---|---|
(
n = 41)
|
(
n = 141)
|
||
Age (years)
|
65.7 ± 9.0
|
65.0 ± 9.6
|
0.69
|
Male sex
|
33 (80.5)
|
102 (72.3)
|
0.12
|
BMI (kg/m
2)
|
20.4 ± 3.2
|
21.0 ± 3.3
|
0.30
|
Systolic blood pressure (mmHg)
|
114.3 ± 15.7
|
119.8 ± 15.4
|
0.0498
|
Diastolic blood pressure (mmHg)
|
68.6 ± 9.1
|
71.7 ± 11.4
|
0.08
|
Antihypertensive medication
|
14 (34.2)
|
37 (26.2)
|
0.32
|
Calcium channel blockers
|
9 (22.0)
|
26 (18.4)
|
0.62
|
RAS inhibitors
|
12 (29.3)
|
19 (13.5)
|
0.02
|
Others
|
5 (12.2)
|
9 (6.4)
|
0.22
|
Cardiovascular disease
|
1 (2.4)
|
9 (6.4)
|
0.33
|
Combination of anticancer drugs
|
32 (78.1)
|
106 (75.2)
|
0.71
|
Cisplatin dose (mg/m
2)
|
73.4 ± 9.6
|
69.8 ± 13.7
|
0.054
|
Amount of hydration (mL/day)
|
3,437 ± 319
|
3,345 ± 595
|
0.20
|
Diuretics
|
38 (92.7)
|
127 (90.1)
|
0.61
|
Non-solid food
|
21 (51.2)
|
50 (35.5)
|
0.07
|
Decreased food intake (≤50%)
|
9 (22.0)
|
18 (12.8)
|
0.15
|
Laboratory data
|
|||
Creatinine (mg/dL)
|
0.69 ± 0.19
|
0.70 ± 0.17
|
0.83
|
CRP (mg/dL)
|
1.01 ± 1.77
|
0.87 ± 1.77
|
0.66
|
Albumin (g/dL)
|
3.80 ± 0.51
|
3.91 ± 0.49
|
0.22
|
Hemoglobin (g/dL)
|
12.7 ± 1.6
|
12.7 ± 1.8
|
0.83
|
Variable
|
Adjusted OR (95%CI)
|
P value
|
---|---|---|
Age
|
1.00 (0.96–1.05)
|
0.87
|
Male sex
|
1.91 (0.79–5.05)
|
0.15
|
Cisplatin dose, 10 mg/m
2
|
1.29 (0.92–1.87)
|
0.14
|
Non-solid food
|
2.09 (0.99–4.50)
|
0.054
|
Systolic blood pressure, 10 mmHg
|
0.75 (0.57–0.95)
|
0.02
|
RAS inhibitors use
|
3.39 (1.30–8.93)
|
0.01
|
Lower blood pressure as a risk of cisplatin nephrotoxicity
Characteristic
|
Nephrotoxicity (+)
|
Nephrotoxicity (−)
|
P value
|
---|---|---|---|
(
n = 71)
|
(
n = 371)
|
||
BMI (kg/m
2)
|
20.0 ± 3.3
|
20.6 ± 3.1
|
0.12
|
Systolic blood pressure (mmHg)
|
112.0 ± 14.7
|
118.5 ± 15.1
|
<0.001
|
Diastolic blood pressure (mmHg)
|
68.3 ± 9.7
|
71.6 ± 11.1
|
0.01
|
Antihypertensive medication
|
20 (28.2)
|
80 (21.6)
|
0.22
|
Calcium channel blockers
|
13 (18.3)
|
58 (15.7)
|
0.60
|
RAS inhibitors
|
14 (19.7)
|
43 (11.6)
|
0.08
|
Others
|
7 (9.9)
|
18 (4.9)
|
0.10
|
Combination of anticancer drugs
|
54 (76.1)
|
299 (80.6)
|
0.42
|
Cisplatin dose (mg/m
2)
|
71.4 ± 10.5
|
68.2 ± 13.3
|
0.03
|
Cumulative cisplatin dose (mg/m
2)
|
135 ± 83
|
152 ± 101
|
0.13
|
Amount of hydration (mL/day)
|
3,441 ± 343
|
3,391 ± 532
|
0.31
|
Diuretics
|
66 (93.0)
|
345 (93.2)
|
0.93
|
Non-solid food
|
38 (53.5)
|
141 (38.0)
|
0.02
|
Decreased food intake (≤50%)
|
12 (16.9)
|
62 (16.7)
|
0.97
|
Laboratory data
|
|||
Creatinine (mg/dL)
|
0.70 ± 0.20
|
0.74 ± 0.21
|
0.12
|
CRP (mg/dL)
|
1.04 ± 1.65
|
0.66 ± 1.45
|
0.08
|
Albumin (g/dL)
|
3.83 ± 0.46
|
3.87 ± 0.45
|
0.43
|
Hemoglobin (g/dL)
|
12.1 ± 1.6
|
11.9 ± 1.8
|
0.37
|